Psyched Wellness Adds Amanita Muscaria Expert To Advisory Board

Kevin Feeney has joined the advisory board of that of Psyched Wellness (CSE: PSYC) as of this morning. Feeney will be working with the company to identify novel uses for the psychoactive constituent in Amanita Muscaria, which is known as Muscimol.

Feeny is a cultural anthropologist and lawyer, whom current serves as program director as well as an instructor in interdisciplinary studies – social sciences at the Central Washington University. Viewed as an expert on the Amanita muscaria mushroom, his primary research is focused on examining legal and regulatory issues that surround psychoactive substances, as well as exploring both the modern and traditional uses of these unique species of mushrooms.

Furthermore, Feeney, whom has a PhD in cultural anthropology, has many publications to his name, including an edited volume on amanita muscaria within Fly Agaric: A Compendium of History, Pharmacology, Mythology, and Exploration, while having also been published in the Journal of Psychoactive Drugs and the International Journal of Drug Policy among others.

Commenting on his appointed as scientific advisor to Psyched Wellness, Feeney stated, “Amanita Muscaria has a long history of use for treating a number of ailments including anxiety, insomnia, pain, and inflammation. While this mushroom has been largely overlooked in both standard and alternative medicines, its potential applications are rich and largely unexplored, and shows promise in such disparate areas as treating alcohol and benzodiazepine withdrawal as well as alleviating cognitive impairments related to Lyme disease and Alzheimer’s.”

The addition to the board of advisors is seen as being a key development within the growth of the company. The experience brought forth by Feeny is expected to assist the company in identifying new novel uses of the compound, in applications for health and wellness.

Psyched Wellness last traded at $0.195 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why Copper Is Heading To $30 And Silver To $200 | Craig Parry

Mako Mining Q3 Earnings: The Transitional Quarter

B2Gold Q3 Earnings: Goose Troubles Cloud The Narrative

Recommended

Emerita Resources Awards Contract For Pre-Feasibility Study On Iberian Belt West Project

Selkirk Copper Appoints Two Members Of Selkirk First Nation To Leadership Team

Related News

Psyched Wellness Sees Professor David Nutt Move From Advisory Role To Directorship

It appears that Professor David Nutt has a desire to become more involved with that...

Monday, November 16, 2020, 08:11:48 AM

Psyched Wellness: Canaccord Pens “Future In Fungi Report”

Yesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could...

Tuesday, March 9, 2021, 11:49:00 AM

Psyched Wellness Submits Trademark For Amanita Muscaria Extract

Psyched Wellness (CSE: PSYC) is looking to build up its portfolio of intellectual property. The...

Thursday, January 21, 2021, 07:01:48 AM

Psyched Wellness Signs Two Year Supply Agreement For Amanita Muscaria

Psyched Wellness (CSE: PSYC) this morning had a brief announcement. Within, the company revealed that...

Tuesday, May 4, 2021, 08:36:07 AM

Psyched Wellness Latest Firm To Conduct Bought Deal Financing

Psyched Wellness (CSE: PSYC) is the latest psychedelics-focused firm to announce a bought deal financing,...

Thursday, January 21, 2021, 07:53:05 PM